Trial · NCT00090285
Results by group59
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 59
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Base Study: Incidence of Human Papillomavirus (HPV) Type 6/11/16/18-related External Genital Warts, Penile/Perianal/Perineal Intraepithelial Neoplasia (PIN), Penile, Perianal or Perineal Cancer | qHPV Vaccine in Base Study | 0.1 | Incidence per 100 person-years | ||
| Base Study: Incidence of Human Papillomavirus (HPV) Type 6/11/16/18-related External Genital Warts, Penile/Perianal/Perineal Intraepithelial Neoplasia (PIN), Penile, Perianal or Perineal Cancer | Placebo in Base Study | 1.0 | Incidence per 100 person-years | ||
| Overall Study: Incidence of HPV Type 6/11-related Genital Warts | qHPV Vaccine in Base Study | 4.3 | 95% Confidence Interval 0.9 to 12.5 | Incidence per 10,000 person-years | |
| Overall Study: Incidence of HPV Type 6/11/16/18-related External Genital Warts, PIN, Penile, Perianal or Perineal Cancer | qHPV Vaccine in Base Study | 3.8 | 95% Confidence Interval 0.8 to 11.1 | Incidence per 10,000 person-years | |
| Overall Study: Incidence of HPV Type 6/11/16/18-related Anal Intraepithelial Neoplasia (AIN) and Anal Cancer | MSM qHPV Vaccine in Base Study | 69.3 | 95% Confidence Interval 25.4 to 150.8 | Incidence per 10,000 person-years | |
| Base Study: Number of Participants With Severe Injection Site Adverse Experiences (AEs) | qHPV Vaccine in Base Study | 25 | Participants | ||
| Base Study: Number of Participants With Severe Injection Site Adverse Experiences (AEs) | Placebo in Base Study | 20 | Participants | ||
| Base Study: Number of Participants With Vaccine-Related Serious Adverse Events (SAEs) | qHPV Vaccine: Base Study and Followup | 0 | Participants | ||
| Base Study: Number of Participants With Vaccine-Related Serious Adverse Events (SAEs) | Placebo: Base Study and Followup | 0 | Participants | ||
| LTFU (EXT2): Number of Participants With Vaccine-Related SAEs | LTFU (EXT2): Early Vaccination Group | 0 | Participants | ||
| LTFU (EXT2): Number of Participants With Vaccine-Related SAEs | LTFU (EXT2): Catch-up Vaccination Group | 0 | Participants | ||
| LTFU (EXT2): Number of Participants Who Died | LTFU (EXT2): Early Vaccination Group | 5 | Participants | ||
| LTFU (EXT2): Number of Participants Who Died | LTFU (EXT2): Catch-up Vaccination Group | 2 | Participants | ||
| Base Study: Substudy to Evaluate the Incidence of HPV 6/11/16/18-related Anal Intraepithelial Neoplasia (AIN) and Anal Cancer in Men Having Sex With Men (MSM) | qHPV Vaccine in Base Study | 1.3 | Incidence per 100 person-years | ||
| Base Study: Substudy to Evaluate the Incidence of HPV 6/11/16/18-related Anal Intraepithelial Neoplasia (AIN) and Anal Cancer in Men Having Sex With Men (MSM) | Placebo in Base Study | 5.8 | Incidence per 100 person-years | ||
| Base Study: Incidence of HPV 6/11/16/18-related Persistent Infection | qHPV Vaccine in Base Study | 0.7 | Infection per 100 person-years | ||
| Base Study: Incidence of HPV 6/11/16/18-related Persistent Infection | Placebo in Base Study | 4.8 | Infection per 100 person-years | ||
| Base Study: Incidence of HPV 6/11/16/18-related Deoxyribonucleic Acid (DNA) Detection | qHPV Vaccine in Base Study | 5.3 | Detection per 100 person-years | ||
| Base Study: Incidence of HPV 6/11/16/18-related Deoxyribonucleic Acid (DNA) Detection | Placebo in Base Study | 10.7 | Detection per 100 person-years | ||
| Geometric Mean Titers to HPV Types 6, 11, 16, and 18 at Month 7 Assessed by Competitive Luminex Immunoassay (cLIA) | qHPV Vaccine in Base Study | HPV Type 6 | 447.7 | 95% Confidence Interval 415.9 to 481.9 | cLIA mMU/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00090285/results